To Check Effectiveness of Medistus Antivirus Lozenges for Cough
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04612829|
Recruitment Status : Completed
First Posted : November 3, 2020
Last Update Posted : November 3, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
A thraot infection sometimes called pharyngitis can be either a bacterial or a viral infection leading to inflammation of the tissues of the throat that causes redness, pain and swelling of the walls and structure of the throat.
The throat or Pharynx is the tube like structure that carries both food to the oesophagus and air to your wind pipe (called the larynx). Infective agents of the throat most often enters through the month or nose. Many of these infections are viral, other can be caused by bacteria such as Streptococcus Pyogenes, or Group A streptococcus.
Symtoms of throat infections most commonly includes pain and a sensation of heat in the throat or Pharynx.
Viral infections accounts for approx. 70% of all pharyngitis. Rhinovirus is the most common cause of viral infections. The other common causes of viral infections in descending order are corona virus, adeno virus, para influenza, and influenza virus. Viral infections are more common during the winter month with the exception of adeno viruses which occur year round.
Viral Pharyngitis is spread through similar mechanism as other viral infections. Hand to mouth contact, contact with oral secretions, and sharing common utensils, all contributes to viral spread.
Prevention of the spread of diseases is based on frequent hand washing, and clinical symptoms of different viruses are more prevalent during certain seasons. Coryza, conjectivitis, malease, or fatigue, hoarseness, and low grade fever such as the presence of viral phayngitis. Subjects with viral pharyngitis can also have atypical symptoms such as mouth breathing, nausea, abdominal pain, and diarrhoea.
Medistus Antivirus is a medical device product with a noble impact. Kistosyn 100 extract contains polyphenols, and with the help of gum arabic, it forms a protective film over the mouth and throat mucus membranes. This protective Barrier lead to a physical (mechanical) barrier against viruses and bacteria which prevent their penetration into body cells, and their further propagation. Due to this physical effect, resistance development is not possible.
|Condition or disease||Intervention/treatment||Phase|
|Throat Infection Pharyngitis Sore Throat||Device: Medistus Antivirus Lozenges||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Open-Label, Randomized, Active Controlled, Single Arm, Study to Ensure the Efficacy and Safety of Medistus Antivirus Lozenges in Mild to Moderate Acute Pharyngitis or Sore Throat or Strep Throat.|
|Actual Study Start Date :||August 23, 2017|
|Actual Primary Completion Date :||October 15, 2017|
|Actual Study Completion Date :||October 15, 2017|
Experimental: Intervention- Medistus Antivirus Lozenges
A blend of Kistosyn Extract with Gum Arabic 1 Lozenge after every 2 hours, 5 times a day. Mode of Administration: Oral Duration of Treatment: 5 days
Device: Medistus Antivirus Lozenges
A blend of Kistosyn Extract with Gum Arabic
- To assess the cough episodes count [ Time Frame: 5 days ]data collection on visit 2 from the subject for improvement in cough count
- Throat pain assessment [ Time Frame: 5 days ]on severity scale of 0-4
- Redness of throat [ Time Frame: 5 days ]on severity scale of 0-4
- Swelling assessment [ Time Frame: 5 days ]on severity scale of 0-4
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patient with mild to moderate acute Pharyngitis or sore throat or strep throat
- Voluntarily signed informed consent for participation in this clinical study
- Compliance by the patient seems guaranteed, and the patient seems to be able to understand and complete the patient diary.
- Severe respiratory tract infection (pneumonia, bronchitis or laryngitis)
- Oro-pharyngeal paresthesia or mycosis
- Severely traumatised and/or very severe oromucosal inflammation
- Peritonsillar abscess
- Long term use (≥ 3 times per week within the last month or regular intake within the last 3 months before randomisation) of antiinflammatory drugs- Any long-acting or slow release analgesic intake including NonSteroidal Anti-Inflammatory Drugs(NSAIDs)within 24 hours before randomisation (e.g. piroxicam or naproxen)
- Any anti-inflammatory drugs intake by systemic route within 12 hours before assigning
- Any paracetamol intake within 6 hours before randomisation
- Any cold medication (decongestant, antihistamine, expectorant, antitussive) within 6 hours before randomisation
- Any topical throat medication intake containing or not a local oral anaesthetic such as lozenge, spray, mouth rinse within 4 hours before recruitment
- Heavy smokers (>20 cigarettes/day)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04612829
|Arogyam Superspeciality Hospital|
|Nagpur, Maharashtra, India, 440025|
|Study Director:||Puneet Mittal||Mittal Global Clinical Trial Services|
|Responsible Party:||Nutrin GmbH|
|Other Study ID Numbers:||
|First Posted:||November 3, 2020 Key Record Dates|
|Last Update Posted:||November 3, 2020|
|Last Verified:||October 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Plan Description:||No plan to share|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
Respiratory Tract Diseases